AAM Calls Out Threat Of Consolidation Among Purchasers
Letter To Authorities Accuses Buying Groups And PBMs Of Anticompetitive Activities
Executive Summary
Drug buying groups and pharmacy benefit managers are leaving generic drug producers unable to compete even when they have viable products due to concentration of buyer power, the Association for Accessible Medicines has highlighted.
You may also be interested in...
Hitting A Moving Target: Teva’s Dethlefs Discusses US Complex Generics
With a number of US complex generic opportunities in Teva’s pipeline, the company’s executive vice president for North America commercial, Sven Dethlefs, talks about the challenges of bringing complex products to market against a backdrop of evolving FDA requirements.
Hitting A Moving Target: Teva’s Dethlefs Discusses US Complex Generics
With a number of US complex generic opportunities in Teva’s pipeline, the company’s executive vice president for North America commercial, Sven Dethlefs, talks to Generics Bulletin about the challenges of bringing complex products to market against a backdrop of evolving FDA requirements.
Industry Speaks Out On Global Antibiotics Shortages
Responding to shortages of antibiotics seen around the world, the IGBA has insisted that the generics industry is working to address spikes in demand and has set out a series of recommendations to mitigate the situation. Meanwhile, US association the AAM has countered suggestions that supply issues are due to a “broken generic drug market.”